Table 1.
Demographic and baseline characteristics of patients.
| Characteristic | Overall (N = 1667) | Non-metastasis (N = 924) | Metastasis (N = 743) | P value |
|---|---|---|---|---|
| Gender, no. (%) | < 0.001 | |||
| Male | 1215(72.9) | 707(76.5) | 508(68.4) | |
| Female | 452(27.1) | 217(23.5) | 235(31.6) | |
| Age, year | 61(54–67) | 61(54–68) | 59(52–67) | 0.001 |
| CEA, ng/ml | 2.82(1.58–7.07) | 2.345(1.37–4.19) | 3.88(1.94–17.25) | < 0.001 |
| CA199, U/ml | 12.46(6.71–36.87) | 10.49(5.95–19.96) | 18.22(8.31–124.7) | < 0.001 |
| CA724, U/ml | 2.98(1.35–9.43) | 2.11(1.17–5.56) | 5.32(1.85–21.31) | < 0.001 |
| Erythrocyte, 1012/l | 4.2(3.7–4.6) | 4.28(3.8–4.67) | 4.07(3.6–4.47) | < 0.001 |
| Hemoglobin, g/l | 124(104–140) | 129(107–143) | 119(102–133) | < 0.001 |
| Leukocyte, 109/l | 5.68(4.51–7.11) | 5.47(4.4–6.8) | 6.04(4.7–7.85) | < 0.001 |
| Neutrophil, 109/l | 3.56(2.67–4.82) | 3.29(2.48–4.29) | 3.97(2.92–5.75) | < 0.001 |
| Lymphocyte, 109/l | 1.42(1.08–1.83) | 1.53(1.18–1.92) | 1.29(0.95–1.67) | < 0.001 |
| NLR | 2.45(1.67–3.83) | 2.1(1.52–3.02) | 3.11(2.08–4.86) | < 0.001 |
| Platelet, 109/l | 207(159–263) | 205(160–259.75) | 209(158–269) | 0.317 |
| Monocyte, 109/l | 0.4(0.29–0.52) | 0.39(0.28–0.5) | 0.4(0.3–0.53) | 0.018 |
| Albumin, g/l | 38.2(34.8–41.4) | 38.6(35.4–41.7) | 37.7(34–40.9) | < 0.001 |
| Globulin, g/l | 26.2(23.4–29.3) | 25.3(22.6–28.2) | 27.4(24.7–30.5) | < 0.001 |
| TNM stagea | – | |||
| I | 146(11.6) | 146(28.1) | – | |
| II | 56(4.4) | 56(10.8) | – | |
| III | 318(25.2) | 318(61.2) | – | |
| IV | 743(58.8) | – | 743 | |
Data are shown as number of cases and percentage or median and interquartile range.
TNM tumor-node-metastasis, NLR neutrophil-to-lymphocyte ratio, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, CA72-4 carbohydrate antigen 72-4.
a404 data missing because some patients were not treated surgically or were treated only with palliative care, resulting in unable to accurately assess the pathological staging.